|Systematic (IUPAC) name|
|Biological half-life||106 hours|
|Molar mass||333.16 g/mol|
Flubromazepam is a benzodiazepine derivative which was first synthesized in 1960, but was never marketed and did not receive any further attention or study until late 2012 when it appeared on the grey market as a novel designer drug.
An alternate isomer, 5-(2-bromophenyl)-7-fluoro-1,3-dihydro-2H-1,4-benzodiazepin-2-one, may have been sold under the same name.
- US 3136815, "Amino substituted benzophenone oximes and derivatives thereof"
- Bjoern Moosmann, Laura M. Huppertz, Melanie Hutter, Armin Buchwald, Sascha Ferlaino, Volker Auwärter (November 2013). "Detection and identification of the designer benzodiazepine flubromazepam and preliminary data on its metabolism and pharmacokinetics". Journal of Mass Spectrometry 48 (11): 1150–1159. doi:10.1002/jms.3279. PMID 24259203.
- B. Moosmann, M. Hutter, L. M. Huppertz, V. Auwärter. "Characterization of the designer benzodiazepines pyrazolam and flubromazepam and study on their detectability in human serum and urine samples" (PDF). Institute of Forensic Medicine, Forensic Toxicology, University Medical Center Freiburg, Freiburg, Germany.
- Lauren C. O'Connor, Hazel J. Torrance, Denise A. McKeown (October 2015). "ELISA Detection of Phenazepam, Etizolam, Pyrazolam, Flubromazepam, Diclazepam and Delorazepam in Blood Using Immunalysis® Benzodiazepine Kit". Journal of Analytical Toxicology. doi:10.1093/jat/bkv122. PMID 26518230.
- "Flubromazepam". New Synthetic Drugs Database.
|This sedative-related article is a stub. You can help Wikipedia by expanding it.|